Aftab Kherani

Aftab serves as Chief Medical Officer and Managing Director of Ajax Health. He also serves as Executive Vice Chairman of current Ajax companies Ablacon, Serpex and Verix, and as a board member of Cortica and Protaryx. He additionally serves as Chairman of Summus Global and on the Board of Visitors of Duke University School of Medicine.

Prior to Ajax, Aftab was a Partner at Aisling Capital, a life science-dedicated investment fund in New York, where he continues to serve as an Operating Partner. While at Aisling, Aftab was actively involved with all aspects of sourcing, diligence, and managing investments in several private and public medtech, biopharma, and diagnostic companies. His historic board involvement includes companies such as Arcus Biosciences (NYSE:RCUS), Loxo Oncology (acquired by Eli Lilly), Spirox (acquired by Entellus), Syros Pharmaceuticals (NASDAQ:SYRS), and TransEnterix (NYSE:TRXC). Prior to Aisling, Aftab was an Engagement Manager at McKinsey & Company, where he was a member of the Pharmaceutical, Medical Product, and Private Equity practices. Before that, Aftab was a Chief Resident in Surgery at Duke University Medical Center, where he completed his residency in general surgery. He also completed a two-year post-doctoral research fellowship investigating treatments for heart failure, valve disease, and arrhythmia at Columbia University, College of Physicians & Surgeons. While at Columbia, he served as an organ procurement fellow as part of the cardiothoracic transplantation team of New York Presbyterian Hospital.

Aftab received his M.D. from Duke University School of Medicine, where he was a Howard Hughes Medical Institute Research Fellowship recipient, and his B.S. in Biology and A.B. in Economics from Duke University, awarded magna cum laude and graduating Phi Beta Kappa.